Oxford University Press Study Points to Effective and Inexpensive Infertility Treatment

PRINCETON, N.J., Feb. 17, 2016 -- An Oxford University Press study points to a promising treatment for male fertility that also reduces miscarriages in women. While men trying to conceive often use preconceptual supplements, little quality data has existed until now. These studies indicate that the precise formulation offered by CellOxess without a prescription provides an effective combination of well-known antioxidant ingredients.

Infertility affects more than one in six couples of reproductive-age, with male infertility accounting for at least 40% of the cases. In most cases, the causes of infertility have remained unknown. Research now identifies “oxidative stress” as a significant factor in infertility.  The stress caused by exposure to chemicals or radiation, poor nutrition, infection and lifestyle habits such as smoking all contribute to a high oxidative burden within the male reproductive tract that in turn impairs the fertilizing potential of the spermatozoa. 

Fertilix® is a carefully formulated preconceptual preparation that counters oxidative damage with antioxidants that support normal sperm function. Data from two separate studies involving mice demonstrated that Fertilix® restores pregnancy rates to normal along with a reduction of fetal resorption (equivalent to miscarriages in women). It does this by protecting sperm cells and the DNA they carry from oxidation during their development and subsequent storage. Damaged sperm DNA is strongly linked with subfertility/infertility as well as higher rates of miscarriage and the appearance of new genetic mutations in children.

The collaborative study between CellOxess and Professor Joël Drevet from the University of Clermont in France and Professor Alfonso Gutiérrez-Adán at the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria or INIA in Spain, was published in the February 2016 issue of “Human Reproduction,” a peer-reviewed scientific journal from University Oxford Press.

Dr. Parviz Gharagozloo, the inventor of Fertilix® formulations, commented, “Unfortunately, oxidative stress is often overlooked as a causative factor in male infertility treatment. We firmly believe appropriate treatment of such patients before conception will significantly help subfertile or infertile couples achieve healthier pregnancies.”

Professor John Aitken, a world leader in sperm biology, from the University of Newcastle in Australia, noted, “If the results observed in mice translate into humans, it will influence clinical practice and provide an inexpensive adjunct therapy to IVF treatment.”

Sold in the USA and internationally, Fertilix® is available in three strengths to provide more personalized treatment options.  This unique strategy minimizes the risk of over-supplementation, which can result in reductive stress, a phenomenon equally damaging to spermatozoa.  IVF Physicians are now coordinating a large multicenter, multinational clinical study to confirm that these results translate into humans.

About CellOxess

Celloxess, LLC, is a privately held biotechnology company headquartered in Princeton, New Jersey, USA. The founder and chief executive officer, Dr. Parviz Gharagozloo, is a medicinal chemist with over 25 years of experience in drug design and development gained in academia, technology transfer and pharmaceutical companies in the UK and the USA. The company has strong research links with university departments pioneering fertility research in Spain, France, Australia, UK and the USA. CellOxess is currently engaged in a human clinical trial with two centers in NJ and PA to demonstrate the utility of diagnostic tests and the treatment efficacy of its first proprietary natural formulation Fertilix®. 

Contact: Norris Clark, (609) 425-1325